Device Trial Radar · NCT01712087
Long-term Surveillance of the MedStream Programmable Infusion System
Last checked: Nov 20, 2026Latest source record: Jan 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Oct 1, 2012
Primary completion
Dec 17, 2017
Study completion Dec 17, 2017
Sponsor
- Lead sponsor
- Codman & ShurtleffNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 23, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-approval study will primarily evaluate the long-term safety of the MedStream Programmable Infusion System when used in combination with Baclofen for the treatment of severe spasticity. A secondary objective, to assess long-term effectiveness, based on the observed scores on the Ashworth Scale (rigidity for the lower extremities) and their Spasm Scores over the 36-month follow-up period will also be described.
Conditions
- Spasticity
Interventions
MedStream Programmable Infusion SystemDevice
Intrathecal Infusion of Baclofen in the Treatment of Spasticity
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the incidence of MedStream system-related Adverse Events (AE)Time frame: 24 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UMass Memorial Medical Center
Worcester, Massachusetts
Methodist Hospital Research Institute
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.